Pharmaceutical Biotechnology

Höfundar: Daan J. A. Crommelin, Robert D. Sindelar, Bernd Meibohm (Útgáfa: 6)
Pharmaceutical Biotechnology

Kaup valmöguleikar

Þessi inngangsbók fjallar um grunnvísindi, framleiðslu, gæði, lyfjaform, lyfjagjöf, efnahagslega þætti og regluverk, auk klínískrar notkunar líftæknilyfja. Hún veitir á einum stað heildstætt námsefni fyrir nemendur í lyfjafræði og skyldum greinum í grunn- og framhaldsnámi. Bókin nýtist einnig vísindafólki í lyfjaiðnaði og háskólasamfélaginu, einkum þeim sem hafa ekki hlotið formlega menntun í lyfjalíftækni og hafa litla reynslu á þessu sviði.

Ör vöxtur og framfarir á sviðinu kölluðu á endurskoðun bókarinnar svo áfram mætti veita nýjustu upplýsingar og kynna lesendum þekkingu og tækni í fremstu röð. Sjötta útgáfan hefur verið uppfærð að fullu og fjallar ítarlegar um nýjar aðferðir og meðferðir, svo sem fákirni, siRNA, mRNA, genameðferð, frumumeðferðir, einstofna mótefni og bóluefni.

Nánar um bókina

Útgefandi
Springer Nature
ISBN
9783031300233
Print ISBN
9783031300226
Format
ePub
Útgáfa
6
Höfundar
Daan J. A. Crommelin, Robert D. Sindelar, Bernd Meibohm
Tungumál
English
Útgefið
2024-01-29
Prent takmörkun á líftíma
100
Prent takmörkun
2
Afritunar takmörkun
2

Kaflar

  • Cover
  • Front Matter
  • Part I. Pharmaceutical Biotechnology: The Science, Techniques, and Important Concepts
  • 1. Molecular Biotechnology: From DNA Sequence to Therapeutic Protein
  • 2. Biophysical and Biochemical Characteristics of Therapeutic Proteins
  • 3. Stability and Characterization of Protein- and Nucleotide-Based Therapeutics
  • 4. Production and Purification of Recombinant Proteins
  • 5. Formulation of Biologics Including Biopharmaceutical Considerations
  • 6. Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins and Nucleic Acids
  • 7. Immunogenicity of Therapeutic Proteins
  • 8. Monoclonal Antibodies: From Structure to Therapeutic Application
  • 9. Genomics, Other “OMIC” Technologies, Precision Medicine, and Additional Biotechnology-Related Techniques
  • 10. Economic Considerations in Medical Biotechnology
  • 11. Biosimilars: Principles, Regulatory Framework, and Societal Aspects
  • 12. An Evidence-Based Practice Approach to Evaluating Biotechnologically Derived Medications
  • Part II. Pharmaceutical Biotechnology: Oligonucleotides, Genes and Cells/Cell Subunits, Vaccines—The Science, Techniques, and Clinical Use
  • 13. Oligonucleotides and mRNA Therapeutics
  • 14. Advanced Therapy Medicinal Products: Clinical, Non-clinical, and Quality Considerations
  • 15. Vaccines
  • Part III. Pharmaceutical Biotechnology: The Protein Products of Biotechnology and Their Clinical Use—Endogenous Proteins and Their Variations
  • 16. Insulin
  • 17. Hematopoietic Growth Factors
  • 18. Recombinant Coagulation Factors and Thrombolytic Agents
  • 19. Follicle-Stimulating Hormone
  • 20. Human Growth Hormone
  • 21. Recombinant Human Deoxyribonuclease I
  • 22. Interferons and Interleukins
  • Part IV. Pharmaceutical Biotechnology: The Protein Products of Biotechnology and Their Clinical Use—Monoclonal Antibodies and Their Variations
  • 23. Antibody-Based Biotherapeutics in Cancer
  • 24. Antibody-Based Biotherapeutics in Inflammatory Diseases
  • 25. Monoclonal Antibodies in Solid Organ Transplantation
  • 26. Antibody-Based Biotherapeutics in Migraine
  • Back Matter